BioAtla, Inc.
BCAB·NasdaqCM
1.2500−0.2500 (−16.67%)today
At close: Oct 12, 3:59 PM EDT · May be delayed up to 15 min · USD
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close1.5000
Open1.3900
Day range1.24001.3900
52-week range1.070071.5000
Off day high−10.07%
Off 52-week high−98.25%
Volume2.59K
Avg. volume (3M)59.44K
Market cap2.08M
EPS (TTM)-25.23
Forward P/E-0.94
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding1.67M
Short interest—
Earnings dateNov 12, 2026 (est.)
Analyst target—
Profit margin—
Against its peers
Compare in full ›| BCAB | PPBT | BOLT | APVO | CRIS | IMMP | |
|---|---|---|---|---|---|---|
| Market cap | 2.08M | — | 8.17M | 3.32M | 1.56M | 27.04M |
| P/E (TTM) | — | — | — | 0.0 | 0.5 | — |
| Forward P/E | -0.9 | — | -0.2 | -0.2 | -0.1 | -0.7 |
| Price/book | -0.1 | — | 0.6 | 0.4 | 0.3 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −96.88% | — | −27.40% | −93.74% | −97.69% | −90.88% |
| Today | −16.67% | — | +3.16% | +2.79% | −4.16% | +0.27% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BCAB news ›Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) ... Context announces buyout of CT-202…
From articles in the 4Search news index.
In the news
1mentions in 30 days
1with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Most coverage from
-
markets.financialcontent.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.